NCT02975843View on ClinicalTrials.gov

Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 21, 2016

Primary Completion Date

March 21, 2017

Study Completion Date

April 11, 2017

Conditions
Chronic Obstructive Pulmonary DiseaseAsthma
Interventions
DRUG

Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium

single inhalation of 99mTc radiolabelled CHF 5993 pMDI (4 puffs for a total dose of: Beclometasone diproprionate (BDP) 400 μg, Formoterol fumarate (FF) 24 μg, Glycopirronium bromide (GB) 50 μg)

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT02975843 - Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients | Biotech Hunter | Biotech Hunter